P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study

Piscaglia, Fabio; Baroni, G. Svegliati; Barchetti, Andrea; Pecorelli, Anna; Marinelli, Sara; Tiribelli, Claudio; Bellentani, Stefano; Bolondi, Luigi; Zoli, Marco; Trevisani, Franco; Malagotti, D.; Bugianesi, E.; Vanni, Ester; Mezzabotta, Lavinia; Cabibbo, Giuseppe; Petta, S.; Guarino, M.

doi:10.1016/s0168-8278(15)30554-7

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be also noted that, in steatotic patients, HCC may develop even in the absence of advanced fibrosis. 47 Development of preventive strategies for NBNC-HCC is also important. Although metformin was reported to reduce HCC risk in diabetic patients, 48 prospective studies are required whether this agent can actually inhibit recurrence after resecting NBNC-HCC, especially steatosis/ DM-based HCC.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics of non‐B non‐C hepatocellular carcinoma without past hepatitis B virus infection

Kimura

Kobayashi

Sakai

et al. 2016

Hepatology Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics of non‐B non‐C hepatocellular carcinoma without past hepatitis B virus infection

Kimura

Kobayashi

Sakai

et al. 2016

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…All these studies performs a defined protocol excluding other etiologies of HCC including Hepatitis C and Hepatitis B virus infection. Risk factors for HCC development in the NASH population included diabetes, age, any previous alcohol consumption and the presence of intra-hepatic iron [ 77 , 79 ]. Interestingly, the use of metformin in patients with type 2 diabetes has been associated with a reduced risk of HCC, suggesting that this risk factor may be modifiable [ 80 ].…”

Section: Hepatocellular Carcinoma (Hcc)mentioning

confidence: 99%

The Natural Course of Non-Alcoholic Fatty Liver Disease

Bertot

Adams

2016

IJMS

486

283

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world, paralleling the epidemic of obesity and Type 2 diabetes mellitus (T2DM). NAFLD exhibits a histological spectrum, ranging from “bland steatosis” to the more aggressive necro-inflammatory form, non-alcoholic steatohepatitis (NASH) which may accumulate fibrosis to result in cirrhosis. Emerging data suggests fibrosis, rather than NASH per se, to be the most important histological predictor of liver and non-liver related death. Nevertheless, only a small proportion of individuals develop cirrhosis, however the large proportion of the population affected by NAFLD has led to predictions that NAFLD will become a leading cause of end stage liver disease, hepatocellular carcinoma (HCC), and indication for liver transplantation. HCC may arise in non-cirrhotic liver in the setting of NAFLD and is associated with the presence of the metabolic syndrome (MetS) and male gender. The MetS and its components also play a key role in the histological progression of NAFLD, however other genetic and environmental factors may also influence the natural history. The importance of NAFLD in terms of overall survival extends beyond the liver where cardiovascular disease and malignancy represents additional important causes of death.

show abstract

“…58 In patients who undergo curative HCC treatment, overall survival is comparable with patients with hepatitis C or alcohol-related HCC. 58,59 Non-alcoholic fatty liver disease subjects without cirrhosis may also develop HCC; however, this is uncommon. 53 Australian data demonstrate one quarter of cases are diagnosed without cirrhosis.…”

Section: Clinical Course Of Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

Burden of non‐alcoholic fatty liver disease in Australia

Mahady

Adams

2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease in the Australian population, although precise estimates of prevalence are lacking. NAFLD may progress to liver fibrosis, cirrhosis, decompensated liver disease, and liver cancer and is becoming an increasingly common indication for liver transplantation in Australia and New Zealand. There is an extrahepatic burden of NAFLD extending beyond the liver, which is manifested by an increased risk of developing cardiovascular disease, diabetes, and chronic renal impairment, all of which are common causes of morbidity in the Australian population. Early recognition of those patients at high risk of developing advanced liver disease is essential in order to target those who will benefit from intensive lifestyle modification. In this review, we present data on the epidemiology of NAFLD within Australia, its associated health burden in terms of hepatic and extrahepatic complications, common clinical presentations, and indications for treatment. We also propose a research agenda that highlights knowledge needed to improve diagnosis and management specific to the Australian context.

show abstract

P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study

Cited by 9 publications

References 0 publications

Clinicopathological characteristics of non‐B non‐C hepatocellular carcinoma without past hepatitis B virus infection

Clinicopathological characteristics of non‐B non‐C hepatocellular carcinoma without past hepatitis B virus infection

The Natural Course of Non-Alcoholic Fatty Liver Disease

Burden of non‐alcoholic fatty liver disease in Australia

Contact Info

Product

Resources

About